EXELExelixisSigning up patients
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Meningioma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- May 21, 2026
- Main results expected
- Feb 29, 2028
- Fully finished
- Sep 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07428616 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC